Lilly Taps Nimbus for Another Obesity Candidate

Mounjaro manufacturer signs deal to develop oral obesity drug

Eli Lilly will use AI in collaboration with Nimbus Therapeutics to develop oral treatments for obesity

Lilly taps Nimbus for another obesity candidate

For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.

Pharma Pulse: Pediatric Vaccine Revisions, COPD Mortality Trends, and Eli Lilly’s $1.3B Obesity Deal

In today’s Pharma Pulse, federal officials slash the childhood immunization schedule, new data underscores the life-saving impact of COVID vaccines for COPD patients, and Eli Lilly targets the AMPK pathway in a massive new oral obesity collaboration.

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface

New York, January 6, 2026, 18:18 EST — After-hours Eli Lilly and Company stock closed up 2.2% on Tuesday and was up about 0.1% in after-hours trading after Nimbus Therapeutics said it struck a research and licensing deal with the drugmaker to pursue an oral obesity treatment. Yahoo Finance The news lands as investors look for the next leg of growth in obesity care, where convenience matters and pill options could widen uptake beyond weekly injec…

Lilly, Nimbus Ink Up-to-$1.3B Oral Obesity Drug Collaboration

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive, worldwide license agreement that could generate more than $1.3 billion for the Boston artificial intelligence (AI)-based drug developer. The collaboration, the second between the companies, will entail Lilly applying Nimbus’ computational chemistry and structure-based dr…